Euromedica 2011 V.S. Dmitruk M.G. Kartalov G.V. Martova S.I. Dmitruk kartalin in the treatment of chronic inflammatory skin conditions"

V.S. Dmitruk M.G. Kartalov G.V. Martova S.I. Dmitruk	KARTALIN IN THE TREATMENT OF CHRONIC INFLAMMATORY SKIN CONDITIONS
	Siberian State Medical University, Tomsk, Russia Astrofarma LLC, Tomsk, Russia

Relevance of the studies. More than one-third of all doctor visits for dermatology conditions are for chronic inﬂammatory skin conditions, including psoriasis and atopic dermatitis. A large number of the clinical variations of these conditions are limited forms that do not require long-term systemic therapy, and their treatment is limited to the use of topical products. Underlying the pathogenesis of these dermatoses are changes in keratinization processes in the epidermis, which invariably lead to an increase in water loss and skin permeability, which promotes local inﬂammation. One of the most original products affecting keratinization processes and restoring the epidermal barrier is Kartalin therapeutic ointment.

Methods and materials. In the ﬁrst stage of the research we studied and treated 100 psoriasis patients in the skin disease clinic of Siberian Medical University. Initial PASI scores were determined for all patients under our care. Patients with mild and moderate psoriasis (PASI up to 50) were selected for the study groups. After 4 weeks the PASI was recalculated and the efﬁcacy of the therapy was assessed according to the results.

The ﬁrst study group А (n=50) received standard treatment in hospital: disintoxicaters, hyposensitizers, and vitamins combined with daily application of Kartalin ointment to the psoriatic papules for 4 weeks. The second group В (n=50) received integrated therapy in hospital for 4 weeks, which included disintoxicators and hyposensitizers, vitamins, indifferent ointments, and topical therapy products.

Group A’s initial PASI was 32.6. Group B’s PASI was 31.4. The PASI of the study groups was calculated at the end of treatment to reﬂect the trend in the regression of the clinical manifestations of psoriasis. In group A it was 13.1 and in group В 18.6. The clinical manifestations of psoriasis exhibited a negative response during treatment in both study groups. At the end of 4 weeks all patients treated had a lower PASI: in group A it fell by 59.8%, in group В by 40.8%. Given the trend in the decline in the groups’ PASI one may state that there was an improvement in the clinic in group A after treatment (a 50% decline in the PASI).

The second part of the study involved examination and treatment of 46 patients with atopic dermatitis. Criteria for inclusion in the group were: adolescence and adulthood; lichenoid clinical forms and squamous clinical forms with licheniﬁcation. Criteria for exclusion from the study groups were: the diffuse form of AD; a severe condition; infancy and childhood; individual intolerance of the ointment’s ingredients, and complications in the form of pyoderma. All patients were representative in age, sex, and duration of the condition.

All the patients were divided into two groups. The ﬁrst group C (n=26) comprised patients who received Kartalin as topical therapy for 2 months. The second group D (n=20) comprised patients who received topical therapy consisting of indifferent and moisturizing ointments and cosmetics. The SCORAD index was used to determine the severity of the atopic dermatitis. At the beginning of the course of treatment the SCORAD equaled: in the ﬁrst group C — 59; in the second group D — 60. At the end of the treatment it was 14 for group C and 18 for group D.

On this basis one may make the following conclusions:

Kartalin is effective in topical treatment of atopic dermatitis (a 76% decrease in the SCORAD index) and may be used as monotherapy for mild and moderate atopic dermatitis with squamous manifestations and licheniﬁcation in outpatient and inpatient settings.
Kartalin is an effective product for topical treatment of psoriasis (reduction in PASI 59.8 %) and may be effectively used in integrated therapy for mild and severe psoriasis.